This is the online version of Adams Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Adam Feuerstein/STAT
SAN FRANCISCO The su… [+725 chars]
Why the JP Morgan conference is important — but not make-or-break - statnews.com
The super-sized gathering of the biopharma universe known as JPM is important, but it’s not going to make or break the year for biotech, Adam Feuerstein writes.
By:Adam Feuerstein
Source:STAT
Published:
Related News
Stock Market Today: Dow Tanks On Greenland Tariff News; Rocket Name Topples (Live Coverage) - Investor's Business Daily
Stock Market Today: The Dow Jones index sank 900 points Tuesday on Trump's Greenland tariff threats. Nvidia is a big loser on the Dow.
Investor's Business Daily
Sony is giving TCL control over its high-end Bravia TVs - Ars Technica
TCL will own 51 percent of the high-end TVs.
Ars Technica•Scharon Harding
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry - CNBC
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
CNBC•Annika Kim Constantino